Skip to main content
. 2018 Apr 20;9(30):21495–21511. doi: 10.18632/oncotarget.25138

Figure 5. Therapeutic response of parental Ln229 cells and Ln229 cells stably expressing split-Renilla luciferase complementation biosensor with different p53 mutants (p53wt, p53Y220C, p53G245S, p53R282W) in response to Doxorubicin (Dox) alone or in combination with PhiKan083, and its associated p53 protein stabilization in cells.

Figure 5

(A) Cells analyzed for apoptosis population 24 h after treatment with Dox (1 μM) alone or in combination with PhiKan083 (100 μM) by PI staining based FACS analysis. (B) Immunoblot analysis for measuring the change in endogenous p53 protein and p53-biosensor protein levels.